论文部分内容阅读
目的:探讨含奥沙利铂(oxaliplatin,OXA)化疗方案联合树突状细胞-细胞因子诱导的杀伤(dendritic cells-cytokine-induced killer,DC-CIK)细胞治疗中晚期原发性肝癌的临床疗效和安全性。方法:回顾性分析2013年1月至2015年6月上海东方肝胆外科医院肿瘤生物治疗科收治的11例中晚期原发性肝癌患者的临床资料,患者均接受以OXA为主的方案化疗,包括FOLFOX 4方案,即OXA+亚叶酸钙(calcium folinatc,CF)+5-氟尿嘧啶(5-fluorouracil,5-FU),或GEMOX方案化疗,即吉西他滨(gemcitabine,GEM)+OXA,化疗结束后2~3 d回输DC-CIK细胞。观察指标包括疾病控制率(disease control rate,DCR)、中位肿瘤进展时间(median time to tumor progression,m TTP)、中位生存期(median overall survival,m OS)和不良反应。结果:11例患者中,获得完全缓解(CR)0例,部分缓解(PR)2例,疾病稳定(SD)5例,疾病进展(PD)4例,总有效2/11例,DCR7/11例;m TTP为4.1个月;m OS为11.3月;主要的不良反应为轻、中度消化道反应、骨髓抑制和轻度周围神经毒性等化疗毒性反应,经对症治疗后均恢复正常。结论:含奥沙利铂化疗方案联合DC-CIK细胞治疗中晚期原发性肝癌具有较好的临床疗效,不良反应较轻,患者耐受性较好,值得进一步研究。
Objective: To investigate the clinical efficacy of oxaliplatin (OXA) chemotherapy combined with dendritic cells-cytokine-induced killer (DC-CIK) cells in the treatment of advanced primary hepatocellular carcinoma And safety. Methods: The clinical data of 11 patients with advanced primary hepatocellular carcinoma who were admitted to the Department of Tumor Biotherapy, Shanghai Oriental Hepatobiliary Surgery Hospital from January 2013 to June 2015 were retrospectively analyzed. All patients received OXA-based regimen including The FOLFOX 4 regimen, OXA + calcium folinatc (CF) + 5-fluorouracil (5-FU) or GEMOX regimen, gemcitabine (GEM) + OXA, d DC-CIK cells were transfused. Observations included disease control rate (DCR), median time to tumor progression (m TTP), median overall survival (m OS) and adverse reactions. Results: Among the 11 patients, there were 0 cases of complete remission (CR), 2 cases of partial remission (PR), 5 cases of stable disease (SD), 4 cases of disease progression (PD), 2/11 cases of total effective and DCR7 / 11 Cases; m TTP for 4.1 months; m OS for 11.3 months; the main adverse reactions of mild to moderate gastrointestinal reactions, bone marrow suppression and mild peripheral neurotoxicity and other chemotherapy toxicity, after symptomatic treatment were back to normal. Conclusion: Oxaliplatin-containing chemotherapy combined with DC-CIK cells in the treatment of advanced primary hepatocellular carcinoma has good clinical efficacy, mild adverse reactions, patients with better tolerance, it is worth further study.